Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting CD36-PPARβ signaling-mediated metabolic adaptation in intratumoral Tregs primes tumors for PD-1 blockade

ABSTRACT: Though high frequency of Tregs in tumor obstructs anti-tumor immune responses, systemic depletion of Tregs caused severe autoimmune disease in mice model. Therefore, specifically targeting intratumoral Tregs is direly needed to fight against tumor. Our study provides a novel approach to target intratumoral Tregs to enhance anti-tumor immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE139325 | GEO | 2020/03/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Targeting CD36-PPARβ signaling-mediated metabolic adaptation in intratumoral Tregs primes tumors for PD-1 blockade

Project description:Targeting CD36-PPARβ signaling-mediated metabolic adaptation in intratumoral Tregs primes tumors for PD-1 blockade

| PRJNA579319 | ENA

Transcriptome analysis of naïve Tregs, memory Tregs and CD161+ Tregs

Project description:Transcriptome analysis of naïve Tregs, memory Tregs and CD161+ Tregs

| PRJNA489005 | ENA

Proteomic analysis of rest and activated Tregs

Project description:The aim of the project is to do proteomic analysis of total cell lysate from rest and activated mouse Tregs. The proteomic data were mapped to the Gene Ontology Cellular Component (GOCC)database to obtain the list of membrane proteins on activated Tregs. The set of membrane proteins identified were compared with the potential Siglec-1 counter-receptors on activated Tregs.

2021-04-28 | PXD022259 | Pride

YTHDF2/m6A/NF-κB axis controls anti-tumor immunity by regulating intratumoral Tregs

Project description:YTHDF2/m6A/NF-κB axis controls anti-tumor immunity by regulating intratumoral Tregs

| PRJNA896248 | ENA

Reprogramming intratumoral Tregs by morpholino-mediated splicing of FOXP3 for cancer immunotherapy

Project description:Regulatory T cells (Tregs) represent a primary barrier to the development of effective anti-tumor immunity. In the clinic, Tregs are a major contributor to the resistance of immune checkpoint blockade (ICB). Preclinical studies have reported complete tumor regression upon Treg depletion in mice. However, systemic depletion of Tregs is detrimental and sometimes lethal as it causes immune-related adverse effects, such as autoimmune diseases. Here, we report that reprogramming Treg functions, by shifting the expression of FOXP3 from its full-length isoform (FOXP3FL) to a short isoform with exon 2 skipped (FOXP3dE2), promotes the tumor-killing activity of T effectors while limiting the adverse effects of Treg depletion. FOXP3dE2 mRNA expression in triple negative breast cancer tissue positively correlates with overall survival of the patients. Mice expressing only the FOXP3dE2 isoform are resistant to the development of various types of tumors, while the littermate wildtype (WT) mice expressing FOXP3FL isoform exhibit significant tumor growth. Intratumoral injection of FOXP3dE2-directing morpholino (dE2 MO) in WT mice markedly increased IFN-.+ CD4 and CD8 T cells in tumors and consequently inhibited the tumor growth. We developed a novel mouse strain with a humanized Foxp3 exon 2 capable of expressing both FOXP3 isoforms through alternative splicing. This mouse strain showed better antitumor immunity than WT mice and dE2 MO treatment can further enhance their antitumor activity. The antitumor activity of dE2 MO was also confirmed using autologous tumor-infiltrating T cells and patient-derived tumor organoids. Taken together, our results suggest that enhancing FOXP3dE2 isoform expression will reprogram tumor infiltrating Tregs and convert these immune suppressive Tregs to helper-like T cells, thus promoting antitumor immunity.

2025-07-10 | GSE286047 | GEO

ATAC-seq data from naïve Tregs, memory Tregs and CD161+ Tregs

Project description:ATAC-seq data from naïve Tregs, memory Tregs and CD161+ Tregs

| PRJNA489004 | ENA

GPR15+ vs GPR15- tumor-associated Tregs

Project description:GPR15+ vs GPR15- tumor-associated Tregs

| PRJNA713801 | ENA

TIGIT+ Tregs

Project description:TIGIT+ Tregs suppress Th1 and Th17 responses while sparing Th2 responses. Analysis of global gene expression of TIGIT+ vs. TIGIT- Tregs from naive mice reveled that TIGIT+ Tregs display an activated phenotype and are enriched for Treg signature genes including the Treg effector molecule Fgl2 which enables them to selectively spare Th2 responses. TIGIT+ and TIGIT- Tregs were sorted from naïve Foxp3-GFP KI mice (pooled spleen and lymph nodes) TIGIT: T cell immunoreceptor with Ig and ITIM domains

2014-12-12 | E-GEOD-56299 | biostudies-arrayexpress

Single-cell RNA sequencing reveals the transcriptomic characteristics of Tregs and TNFR2+ Tregs isolated from tumor tissues and peripheral blood of patients with gastric cancer

Project description:This study aimed to explore the characteristics and role of TNFR2+ Tregs in the microenvironment and progression of gastric cancer by single-cell RNA sequencing.We obtained Tregs from tumor tissues and peripheral blood of three GC patients.Through single-cell RNA sequencing, we found tumor-infiltrating Tregs express high levels of TNFR2. The TNF-a/TNFR2 signaling pathway is activated, accompanied by upregulation of costimulatory molecules. Compared to blood Tregs, tumor-infiltrating Tregs exhibit activated and effector states. In addition to expressing costimulatory molecules such as TNFR2, 4-1BB, OX40 and GITR, tumor-infiltrating Tregs are also characterized by high expression of immune checkpoints such as CTLA-4 and TIGIT and chemokines such as CCR6.This study revealed a high infiltration level of TNFR2+ Tregs with the characteristics of activated and effector Tregs in the tumor microenvironment. Our study provides a new theoretical basis for TNFR2+ Tregs as a therapeutic target in gastric cancer.

2021-04-16 | GSE172131 | GEO

Tregs recruited to the omentum and spleen express distinct transcriptomes

Project description:To test whether Tregs that were newly recruited to tumor-bearing omentum had similar properties to those of adipose resident Tregs, we surgically joined tumor-bearing mice with congenic naive mice, sorted partner-derived Tregs from the omenta and spleens of tumor-bearing (CD45.1+) parabionts on day 14 and performed RNAseq analysis

2022-02-25 | GSE181124 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data